0690 (0690) Fair Value & Analysis

Healthcare · Market cap HK$519M

0 0690 0690 · HK

PriceHK$0.0870

Fair ValueHK$0.2114

Upside+143.0%

Quality51/100

Evidence: High Range HK$0.1244 – HK$0.3506

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −2.2% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.0820 – HK$0.1593 · fair‑value band HK$0.1244 – HK$0.3506 · the HK$0.0870 price screens below the HK$0.2114 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0690 (0690) currently trades at HK$0.0870, while our model-based Fair Value estimate is HK$0.2114 — implying the stock looks roughly 143.0% undervalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 0690 generated revenue of HK$586M at a net margin of 15.9%. Revenue declined 1.2% year over year. It earns a return on equity of 25.3%. The balance sheet holds a net cash position of HK$82.1M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$586M

Revenue growth (YoY) -1.2%

Net margin 15.9%

Return on equity 25.3%

Free cash flow HK$38.1M FY2025

P/E ratio 4.4

More key figures

Operating margin 6.5%

EPS (TTM) HK$0.0100

Dividend yield 3.3%

EPS growth (YoY) +14.4%

Net cash HK$82.1M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0690 reported revenue of HK$586M in FY2025 versus HK$353M in FY2021, a compound +13.5%/yr. Reported net income was HK$93.3M in FY2025.

Revenue +13.5%/yr

FY21 HK$353M

FY22 HK$440M

FY23 HK$485M

FY24 HK$553M

FY25 HK$586M

Net income

FY21 −HK$19.6M

FY22 HK$38.5M

FY23 HK$70.9M

FY24 HK$82.8M

FY25 HK$93.3M

Is 0690 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	7,746 MXN	5,617 MXN	-27%
Regeneron Pharmaceuticals, Inc REGN	$635.45	$547.01	-14%
UCB SA UCB	€247.60	€180.06	-27%
argenx SE ARGNF	$900.00	$382.64	-57%
Alnylam Pharmaceuticals, Inc ALNY	$286.41	$106.81	-63%
Samsung Biologics Co 207940	1,000,000 KRW	1,091,384 KRW	+9%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0690 (0690) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.2114 versus a price of HK$0.0870 — about +143% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 0690?

Our model-based fair value for 0690 is HK$0.2114 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.0870.

What is the quality score of 0690?

0690 has a Quality Score of 51/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0690 (0690)?

0690 reported trailing-twelve-month revenue of about HK$586M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0690?

The net profit margin of 0690 is about 15.9%, meaning it keeps roughly 15.9% of revenue as net income. Based on the latest reported figures.

Does 0690 pay a dividend?

0690 currently shows a dividend yield of about 3.33% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.